Amplification of TRIM44: Pairing a Prognostic Target With Potential Therapeutic Strategy

Conclusions
Genomic amplification drives TRIM44 overexpression in EGCs and BCs. Targeting the mTOR pathway provides a potential therapeutic option for TRIM44-amplified tumors.

Source: JNCI - May 16, 2014 Category: Cancer & Oncology Authors: Ong, C.-A. J., Shannon, N. B., Ross-Innes, C. S., O'Donovan, M., Rueda, O. M., Hu, D.-e., Kettunen, M. I., Walker, C. E., Noorani, A., Hardwick, R. H., Caldas, C., Brindle, K., Fitzgerald, R. C. Tags: Article Source Type: research